Your browser doesn't support javascript.
loading
A pilot study of the effect of rivaroxaban in sickle cell anemia.
Ataga, Kenneth I; Elsherif, Laila; Wichlan, David; Wogu, Adane F; Matsui, Neil; Pawlinski, Rafal; Cai, Jianwen; Key, Nigel S.
Affiliation
  • Ataga KI; Center for Sickle Cell Disease, University of Tennessee Health Scienter Center, Memphis, Tennessee, USA.
  • Elsherif L; Center for Sickle Cell Disease, University of Tennessee Health Scienter Center, Memphis, Tennessee, USA.
  • Wichlan D; Division of Hematology and Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Wogu AF; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Matsui N; Vanguard Therapeutics, Inc., Half Moon Bay, California, USA.
  • Pawlinski R; Division of Hematology and Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Cai J; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Key NS; Division of Hematology and Blood Research Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Transfusion ; 61(6): 1694-1698, 2021 06.
Article in En | MEDLINE | ID: mdl-33660875

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Aromoterapia Main subject: Blood Coagulation / Factor Xa Inhibitors / Rivaroxaban / Anemia, Sickle Cell Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Transfusion Year: 2021 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Therapeutic Methods and Therapies TCIM: Terapias_biologicas / Aromoterapia Main subject: Blood Coagulation / Factor Xa Inhibitors / Rivaroxaban / Anemia, Sickle Cell Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Transfusion Year: 2021 Type: Article Affiliation country: United States